NCPA submitted comments to CMS on its draft guidance to the Medicare Drug Price Negotiation Program (MDPNP). Among other things, NCPA stressed that manufacturers should pay pharmacies timely, meaning within 14 days of the pharmacy adjudicating the claim with the plans/PBMs. NCPA argued that CMS must ensure that neither plans, PBMs, manufacturers, wholesalers, CMS, nor any other entity be allowed to assess any fee on pharmacies to effectuate any aspect of the MDPNP whatsoever, and that any EFT fees should be borne by the manufacturer and not the pharmacy.
For NCPA's talking points on the MDPNP, click here.
NCPA
